Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00284739
Other study ID # HI-03HYoon-02
Secondary ID
Status Completed
Phase Phase 2
First received January 31, 2006
Last updated February 24, 2015
Start date February 2006
Est. completion date October 2007

Study information

Verified date February 2015
Source Kaiser Permanente
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Intracavitary injection of low dose alteplase into loculated abdominopelvic abscesses will reduce the duration of percutaneous drainage and increase the proportion of successful drainages.


Description:

The use of fibrinolytics for the percutaneous drainage of loculated pleural effusions has been shown to reduce the catheter dwell time and to improve drainage of the effusions. Abscesses in the abdomen and pelvis are often loculated which makes percutaneous drainage difficult. We hypothesize that the infusion of alteplase via a drainage catheter into the loculated abscess collections of the abdomen and pelvis will similarly decrease catheter dwell time and improve overall abscess drainage. The direct injection of Activase into abscess cavities utilizes a very low dose of drug within a closed environment which should not be associated with any significant risk of hemorrhage. To date, there does not appear to be a significant risk of systemic hemorrhagic complications associated with the use of intracavitary thrombolytics for the drainage of abdominopelvic abscesses although only a few such studies have been reported. We hope to prove that the use alteplase for intracavitary thrombolysis improves outcomes associated with percutaneous catheter drainage of loculated abscess collections without increasing complications or costs.

The design of the trial will be as a single-center, prospective, open-label, randomized trial comparing the infusion of Activase versus saline for treatment of loculated abdominopelvic abscesses requiring percutaneous drainage. Patients with loculated abdominopelvic abscesses who are referred for percutaneous drainage will be eligible for this study. Patients will undergo standard placement of a 10-12 french percutaneous drain into their abscess cavity under computed tomography guidance. If the entire contents of the abscess cavity cannot be aspirated at the time of initial catheter placement, the abscess will be assumed to be loculated. The patient will then be randomized to have their abscess catheter irrigated twice a day with a volume of fluid approximately equal to the one-half the residual volume of the abscess. In the control group, the normal saline will be fluid instilled into the abscess cavity. The study group will receive Activase reconstituted in sterile water and then diluted to the appropriate volume with normal saline.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 2007
Est. primary completion date October 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Ability to provide written informed consent and comply with study assessments for the full duration of the study.

- Age > 18 years

- Adult, non-gravid patients with loculated abdominopelvic abscesses immediately after percutaneous drainage will be eligible to participate. A loculated abscess is defined as an abscess whose contents cannot be completely drained at the time of initial catheter placement as documented on CT.

Exclusion Criteria:

- Active internal bleeding, involving intracranial and retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts

- History of stroke within 6 months

- Uncorrectable bleeding diathesis (INR > 1.3 despite therapy)

- Recent intracranial or intraspinal surgery or trauma

- Pregnancy (positive pregnancy test)

- Pancreatic abscesses

- Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated

- Participation in another simultaneous medical investigation or trial

- Participation in another clinical investigation within previous 30 days of catheter placement

- Prior enrollment in the study

- Known allergy to Alteplase or any of its components

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Alteplase
2mg or 4mg given twice daily for three days into loculated abscess
Other:
saline
saline injection twice daily for three days

Locations

Country Name City State
United States Kaiser Foundation Hospital Honolulu Hawaii

Sponsors (2)

Lead Sponsor Collaborator
Kaiser Permanente Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage 30 days No
Secondary Percentage of Loculated Abscesses Which Completely Resolve With Percutaneous Drainage Alone at the First Follow-up CT Scan Performed 3 Days After Initial Drain Placement This is the percentage of participants in whom their loculated abscess completely resolve with percutaneous drainage at the time of the first followup CT performed at 3 days after start of the intervention and therefore do NOT require additional surgical intervention. 3 days No
Secondary Duration (in Days) of Percutaneous Drainage. The total number of days that the drainage catheter was left in place from the time of randomization until the time of catheter removal. The maximum duration of measurement for this outcome was up to 30 days. Up to 30 days No
See also
  Status Clinical Trial Phase
Completed NCT00515034 - A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia Phase 2
Recruiting NCT02688244 - Irrigation Versus Suction in Complicated Acute Appendicitis N/A
Completed NCT01568853 - A Prospective Study of The Complement Depletion in Patients With Severe Abdominal Sepsis N/A
Completed NCT00136201 - Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections Phase 3
Completed NCT00931554 - Randomized Trial of Early Versus Standard Drainage Removal After Pancreatic Resections N/A
Completed NCT03681665 - Use of Iterative Reconstruction Method in Ultralow-dose CT for Follow-up of Patients With Intraabdominal Abscess: Comparison With Standard Dose CT
Completed NCT01597336 - Treatment of Abdominal Abscesses With or Without Fibrinolysis N/A
Completed NCT01283815 - Laparoscopic Management of Periappendicular Abscess Phase 2
Completed NCT05283733 - Open to Laparoscopic Reverse Conversion of Perforated Appendicitis N/A
Terminated NCT01110382 - A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections Phase 3
Completed NCT00488306 - Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI Phase 4
Recruiting NCT03815370 - A Non-Traumatic Binder for Temporary Abdominal Wall Closure N/A
Recruiting NCT03476941 - Antibiotic Irrigations for Intra-Abdominal Drains Phase 2